D,L-Lysine-Acetylsalicylate + Glycine (LASAG) Reduces SARS-CoV-2 Replication and Shows an Additive Effect with Remdesivir

Jungwirth, Johannes; Haring, C. M.; König, Sarah; Giebeler, Liane; Doshi, Heena; Brandt, Christian; Deinhardt‐Emmer, Stefanie; Löffler, Bettina; Ehrhardt, Christina

doi:10.3390/ijms23136880

Cited by 2 publications

(1 citation statement)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The utilization of aspirin showed a notable connection with lower mortality rates in individuals diagnosed with COVID-19 [101]. In a prior in vitro study, aspirin was noted to have the potential to decrease RNA synthesis and replication of human coronavirus strains such as CoV-229E and Middle-East-respiratory-syndrome-coronavirus (MERS-CoV) [102]. However, due to a limited number of comprehensive studies, a conclusive determination about aspirin's impact on the occurrence of both blood clotting and bleeding events in COVID-19 patients could not be established.…”

Section: Identi Cation Of Druggable Targetsmentioning

confidence: 99%

In-silico analysis of SARS-CoV-2 N protein host interactors involved in Parkinson’s Disease and Dementia

Jain,

Naithani,

Prakash

et al. 2024

Preprint

View full text Add to dashboard Cite

Severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) is a highly pathogenic and contagious coronavirus that first surfaced in late 2019. The genome encodes four major structural proteins, non-structural proteins and accessory proteins. The nucleocapsid (N) protein of SARS-CoV-2 is an evolutionarily conserved RNA-binding protein that is abundant and plays a critical role in packaging the viral genome. Researchers have explored its potential as a target for therapeutic purposes. People with pre-existing neurological conditions like Parkinson’s disease (PD) and dementia have been recognised as a high-risk population for severe COVID-19 illness as SARS-CoV-2 has been reported to cause deterioration of the symptoms of these diseases. This study aims to identify the shared human interactors of SARS-CoV-2 N protein, PD and dementia. Proteins involved were retrieved from databases, and protein-protein interaction networks were created and visualized in Cytoscape. Individual intersection networks of SARS-CoV-2 N protein with PD and dementia resulted in 46 and 26 proteins, respectively, while intersection networks of SARS-CoV-2 N protein, PD and dementia resulted in 15 common proteins. Seed proteins were identified from network clusters and their Gene Ontology (GO) analysis revealed their involvement in several biological processes. Valosin-containing-protein (VCP) was found to be the only seed protein involved during the co-occurrence of SARS-CoV-2 N protein infection, PD and dementia and is mainly concerned with the regulation of the ubiquitin-proteasome system (UPS). Further, gene enrichment analysis of the identified 15 common proteins was conducted using the DAVID tool, followed by the identification of 7 druggable targets using the Therapeutic Target Database (TTD) and DrugBank. Studying the biological functions of the identified host-protein interactors is crucial for understanding the progression of the disease at a molecular level. Moreover, approved therapeutic compounds against the potential drug target proteins can also be utilized to develop effective treatments.

show abstract

Section: Identi Cation Of Druggable Targetsmentioning

confidence: 99%

In-silico analysis of SARS-CoV-2 N protein host interactors involved in Parkinson’s Disease and Dementia

Jain,

Naithani,

Prakash

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

The Local Anaesthetic Procaine Prodrugs ProcCluster® and Procaine Hydrochloride Impair SARS-CoV-2 Replication and Egress In Vitro

Häring,

Jungwirth,

Schroeder

et al. 2023

IJMS

View full text Add to dashboard Cite

As vaccination efforts against SARS-CoV-2 progress in many countries, there is still an urgent need for efficient antiviral treatment strategies for those with severer disease courses, and lately, considerable efforts have been undertaken to repurpose existing drugs as antivirals. The local anaesthetic procaine has been investigated for antiviral properties against several viruses over the past decades. Here, we present data on the inhibitory effect of the procaine prodrugs ProcCluster® and procaine hydrochloride on SARS-CoV-2 infection in vitro. Both procaine prodrugs limit SARS-CoV-2 progeny virus titres as well as reduce interferon and cytokine responses in a proportional manner to the virus load. The addition of procaine during the early stages of the SARS-CoV-2 replication cycle in a cell culture first limits the production of subgenomic RNA transcripts, and later affects the replication of the viral genomic RNA. Interestingly, procaine additionally exerts a prominent effect on SARS-CoV-2 progeny virus release when added late during the replication cycle, when viral RNA production and protein production are already largely completed.

show abstract

D,L-Lysine-Acetylsalicylate + Glycine (LASAG) Reduces SARS-CoV-2 Replication and Shows an Additive Effect with Remdesivir

Cited by 2 publications

References 81 publications

In-silico analysis of SARS-CoV-2 N protein host interactors involved in Parkinson’s Disease and Dementia

In-silico analysis of SARS-CoV-2 N protein host interactors involved in Parkinson’s Disease and Dementia

The Local Anaesthetic Procaine Prodrugs ProcCluster® and Procaine Hydrochloride Impair SARS-CoV-2 Replication and Egress In Vitro

Contact Info

Product

Resources

About